<DOC>
	<DOCNO>NCT00180596</DOCNO>
	<brief_summary>The purpose study evaluate benefit biventricular pacing patient heart failure receive optimal pharmacological therapy , either without ICD indication</brief_summary>
	<brief_title>PACMAN - PAcing CardioMyopathies , EuropeAN Study</brief_title>
	<detailed_description>Heart Failure syndrome affect million patient Europe half million new case report annually . Drug therapy conventional treatment choice emergence cardiac resynchronization therapy ( CRT ) biventricular pace deliver heart pacemaker implantable cardioverter defibrillator . This study design assess effect CRT patient optimize conventional heart failure medication include diuretic , beta blocker ACE inhibitor . The effect CRT evaluate comparison 6 minute walk performance , Quality Life NHYA class 6 month CRT therapy either program ON OFF . In addition , evaluation incidence adverse event ( predefined ventricular arrhythmia , hospitalization , drop-outs , complication patient death ) do group 6 month . Patients program ON 6 month data collect additional 6 month .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>NYHA Class III IV EF &lt; 35 % ; Optimal individual drug therapy 2 week prior enrollment include ACE inhibitor ; beta blocker diuretic unless tolerate Reduced life expectancy &lt; 6 month candidate heart transplant within 6 month ; chronic/recurrent atrial fibrillation/flutter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2005</verification_date>
</DOC>